Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Cerilliant
Covington
Citi
Cipla
Harvard Business School
Medtronic
Johnson and Johnson
Federal Trade Commission

Generated: April 21, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,866,591

« Back to Dashboard

Summary for Patent: 5,866,591
Title: Stable formulations of remifentanil
Abstract:Stable formulations of 3-[4-methoxycarbonyl-4-[(1 -oxopropyl)phenylamino]-1-piperidine]propanoic acid, methyl ester, generally referred to as remifentanil, are disclosed. In particular, stabilized lyophilized solid composition are disclosed comprising certain acids, most preferably comprising glycine.
Inventor(s): Gatlin; Larry Alan (Chapel Hill, NC), Heiman; Shirley Ann (Cary, NC), Lewis; Janet Sue (Cary, NC)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:08/926,930
Patent Claims: 1. A solid composition comprising remifentanil and glycine, wherein said composition maintains a room temperature shelf life stability of at least two years.

2. The composition of claim 1 wherein said composition is a lyophilized solid composition.

3. A solid composition comprising remifentanil and at least one agent selected from the group consisting of ascorbic acid, citric acid, maleic acid, phosphoric acid, glycine, succinic acid, or tartaric acid.

4. The composition of claim 3 wherein said composition comprises less than 3% by weight water.

5. The composition of claim 3 wherein said agent is glycine.

6. The composition of claim 5 further comprising sodium chloride, polyvinylpyrolidone, or mannitol.

7. The composition of claim 5 wherein remifentanil and glycine comprise at least 20% by weight of the composition.

8. The composition of claim 5 wherein remifentanil and glycine comprise at least 50% by weight of the composition.

9. The composition of claim 5 wherein said composition gives an aqueous solution having a pH of from pH 1.5 to pH 5, when dissolved in an amount of aqueous liquid to give a composition suitable for intravenous administration to a patient.

10. The composition of claim 5 wherein said composition gives an aqueous solution having a pH of from pH 2.5 to pH 3.5, when dissolved in an amount of aqueous liquid to give a composition suitable for intravenous administration to a patient.

11. The composition of claim 5 wherein said composition gives an aqueous solution having a pH of from pH 2.8 to pH 3.2, when dissolved in an amount of aqueous liquid to give a composition suitable for intravenous administration to a patient.

12. The composition of claim 5 wherein said composition is lyophilized.

13. The composition of claim 12 wherein said composition is sterilized.

14. The composition of claim 5 wherein the ratio by weight of other components to remifentanil is less than or equal to 75 to 1.

15. The composition of claim 5 wherein the ratio by weight of other components to remifentanil is less than or equal to 40 to 1.

16. The composition of claim 5 wherein the ratio by weight of other components to remifentanil is less than or equal to 15 to 1.

17. The composition of claim 5 wherein glycine comprises at least 50% by weight of the composition.

18. The composition of claim 5 wherein said composition comprises, for each part by weight of remifentanil free base or hydrochloride salt, from 2 to 20 parts by weight of glycine, and from 0 to 50 parts by weight of other ingredients.

19. A complex of remifentanil hydrochloride, glycine, and water.

20. Remifentanil glycinate.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Farmers Insurance
Argus Health
Julphar
QuintilesIMS
Medtronic
Dow
UBS
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.